The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
ACLARA BioSciences, Inc. and the USC/Norris Comprehensive Cancer Center and Hospital have entered into a research partnership to identify and characterize novel clinical biomarkers for cancer. The partners will initially apply ACLARA's proprietary multiplexed eTag Assay System to the discovery of biomarkers for breast cancer. The eTag assays will be developed to focus on profiling Epidermal Growth Factor Receptor (EGFR) family signal transduction pathways. Amersham Biosciences, the life sciences business of Amersham plc has launched its GenomiPhi DNA Amplification Kit to simplify the DNA preparation process and enable high-quality DNA to be prepared from limited biological material. The isothermal method employed by GenomiPhi DNA Amplification Kit allows microgram quantities of DNA to be produced overnight from nanogram amounts of starting material. Ipsogen has introduced a line of FusionQuant Kits that allows the standardization and quantitative analysis of a range of fusion gene transcripts for use in minimal residual disease studies, including gene transcripts: m-BCR and TEL-AML1. Molecular Probes, Inc. and LightUp Technologies AB announced that LightUp Technologies will launch DNA analysis products, including diagnostic assays, using unique fluorescence-based technology newly licensed from Molecular Probes. The LightUp Probe products can be used to identify and quantify the presence of bacteria, viruses and other pathogens. The kits are expected to launch in May 2003. Nanogen, Inc. has introduced Analyte Specific Reagents for identifying mutations linked to Alzheimer's and Canavan diseases and a research use only product for beta thalassemia that can be utilized on the NanoChip Molecular Biology Workstation. Thermo Electron Corporation and Quest Diagnostics Incorporated have developed an automated, biochip-based laboratory test for the detection of cystic fibrosis (CF) gene mutations during prenatal screening. The CF Portrait biochip is designed and manufactured by Thermo Electron's Thermo BioStar unit, part of the company's Clinical Diagnostics division, and uses its proprietary Optical ImmunoAssay (OIA) technology. The biochip is used in conjunction with Quest Diagnostics' DNA extraction and amplification methods. Quest Diagnostics has exclusive rights to incorporate the CF Portrait biochip into its laboratory-developed testing methods, and its Nichols Institute Diagnostics subsidiary has exclusive rights to further develop the biochip as part of a testing system for laboratories worldwide.
Molecular Biology - March 2003
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: May 1, 2003 |